UCF | Environmental Health and Safety
UNIVERSITY OF CENTRAL FLORIDA

SAFETY Meeting Minutes
IBC Committee
Zoom

MEETING TIME RECORDS

Meeting start time: 8/13/2025 3:02 PM
Meeting end time: 3:48 PM

VOTING MEMBER ATTENDANCE

Name of Regular/Alternate Member	Status (Member or Alternate)	Present by Teleconference?
Karl McKinstry	Member	X
Gregory Danyluk	Member	X
Melina Kinsey	Member	X
Kyle Rohde	Member	Absent
Stanley Haimes	Member	X
Hubert Salvail	Member	X
Judith Hecker	Member	X
Lane Coffee	Vice-Chair, Member	X
Yulia Gerasimova	Member	X
Teresa Krisch	Member	X

QUORUM INFORMATION

Number of SAFETY members on the roster: 9
Number required for quorum: 5

All members present by teleconference received all pertinent material before the meeting and were able to actively and equally participate in all discussions.

ATTENDANCE STATUS AND VOTING KEY

ABSTAIN:	Present for the vote, but not voting "For" or "Against."
ABSENT:	Absent for discussion and voting for reasons other than a conflicting interest.
RECUSED:	Absent from the meeting during discussion and voting because of a conflicting interest.
SUBSTITUTION:	When regular members and their alternate(s) are listed in the ATTENDANCE table above and an alternate member substitutes for the

	regular member this identifies the name of the alternate to indicate which individual is serving as the voting member for this vote. May be deleted if there are no substitutions.

GUEST NAMES
Sophia Vermeulen – Biosafety Specialist

Previous Meeting minutes approved: Yes

REVIEW OF SUBMISSIONS

This meeting was Chaired by the Vice-Chair, Lane Coffee.

Initial Protocol

1. Review of SPROTO202500000013

Title:	Transfer RNA interrogation - Gerasimova
Investigator:	Yulia Gerasimova
Submission ID	SPROTO202500000013
Funding:	None
Documents Reviewed:	• 18-21_Gerasimova_190405 (002).pdf
Agents:	• Saccharomyces cerevisiae
Agent Containment:	Biological Containment Levels: • Saccharomyces cerevisiae: BSL-1
Applicable NIH Guidelines:	None

a. **Determination:** Approved
Moved: Greg Danyluk
Second: Hubert Salvail

b. **Required modifications: None**

c. **Votes:**
For: 8
Against: 0
Recused: 1 Gerasimova
Absent: 1
Abstained: 0

De Novo Review

2. Review of SPROTO202500000012

Title:	Bacterial DNA/RNA detection - Gerasimova
Investigator:	Yulia Gerasimova
Submission ID	SPROTO202500000012
Funding:	• Name: National Institute of Allergy and Infectious Diseases (NIAID), Grant Office ID: , Funding Source ID: R01AI149468
Documents Reviewed:	• 18-20_Gerasimova_190404.pdf
Agents:	• Bacillus subtilis • Escherichia coli K12 or derivative • Mycobacterium smegmatis • Pseudomonas aeruginosa • Staphylococcus aureus
Agent Containment:	Biological Containment Levels: • Pseudomonas aeruginosa: BSL-2 • Bacillus subtilis : BSL-1 • Escherichia coli K12 or derivative: BSL-1 • Mycobacterium smegmatis: BSL-1 • Staphylococcus aureus: BSL-2
Applicable NIH Guidelines:	None

a. **Determination:** Modifications Required
Moved: Karl McKinstry
Second: Judy Hecker

b. **Required modifications:**
1. Summary of Research – The last sentence, "The technology proposed here is promising for diagnostics of TB, as well as other pathogens, \ particularly in resource-constrained high-burden countries, which may revolutionize healthcare worldwide." What are the "other pathogens?"
2. Protocol Team Members – One Graduate Student is marked as Not involved with procedures. Only list personnel who are involved in the procedures.
3. Funding Sources – Is the grant still applicable to this research?
4. Recombinant or Synthetic Nucleic Acid Work Description –
   - In the Recombinant or Synthetic Nucleic Acid Work Descriptions section of the protocol, the investigator is mentioning that genomic DNA for the strains to be studied will be either extracted

or obtained from Kyle Rohde's lab or BEI. The provided description is basically a copy-paste of the information provided in section 2 of Recombinant or Synthetic Nucleic Acids Usage. As genomic DNA is not considered recombinant nucleic acid, the part describing how gDNA will be obtained or extracted should be removed from the section 1 of Synthetic Nucleic Acid Work Description.

- The information about the genes that will be interrogated in the bacterial species to be studied should be provided in section 2 of Synthetic Nucleic Acid Work Description. These genes are endogenous to the bacterial species, and are therefore not recombinant.

c. **Votes:**

For:	8	
Against:	0	
Recused:	1	Gerasimova
Absent:	1	
Abstained:	0	

Amendment

3. Review of SAMEND202500000011

Title:	Amendment for SPROTO202200000046 - Alexander
Investigator:	Kenneth Alexander
Submission ID	SAMEND202500000011
Funding:	None
Documents Reviewed:	• MigrationPlaceholder • MigrationPlaceholder • 21-26_Nemours_Alexander 082222.pdf • Nemours SOP_Working with Zika virus • Nemours SOP_Working with BSL-2 Agents • Answer about Spondweni virus.pdf • Spondeweni Virus_BEI Information Sheet • Spondeweni Virus_ArboCat Information Sheet • SOP "Safe Handling of Cholera Toxin"
Applicable NIH Guidelines:	None

a. **Determination:** Modifications Required
Moved: Judy Hecker

Second: Yulia Gerasimova

b. **Required modifications:**

1. Select Agents or Toxins - Question #1; Cholera toxin listed as BSL-1 – should be BSL-2 because it must be worked with in a BSC.

2. Waste Management – Question #3; For incidents, change it to say "and UCF Environmental Health and Safety" not "and/or"

c. **Votes:**

For:	9
Against:	0
Recused:	0
Absent:	1
Abstained:	0

De Novo Review

4. Review of SPROTO202500000014

Title:	Doxorubicin-ES-Exosomes - Singla
Investigator:	Dinender Singla
Submission ID	SPROTO202500000014
Funding:	• Name: National Institutes of Health (NIH), Grant Office ID: , Funding Source ID:
Documents Reviewed:	• Previous BARA application
Agents:	• Other Cell Lines
Agent Containment:	Biological Containment Levels: • Other Cell Lines: BSL-2
Applicable NIH Guidelines:	None

a. **Determination:** Modifications Required

Moved: Yulia Gerasimova
Second: Teresa Krisch

b. **Required modifications:**

1. Summary of Research - Clarify if you are using actual mice or just primary cell lines. If using mice please describe scope of research.

c. **Votes:**

For:	9
Against:	0
Recused:	0
Absent:	1

Abstained: 0

De Novo Review

5. Review of SPROTO202500000018

Title:	All things tuberculosis - Rohde
Investigator:	Kyle Rohde
Submission ID	SPROTO202500000018
Funding:	• Name: National Institutes of Health (NIH), Grant Office ID: AWD00001002 , Funding Source ID: R21AI159191 • Name: National Institutes of Health (NIH), Grant Office ID: AWD00000182, Funding Source ID: R01AI149468
Documents Reviewed:	None
Agents:	• Mycobacterium tuberculosis • Lymphatic • Respiratory Tissue • THP-1 • Other Cell Lines • H9C2: rat cardiomyoblast • J774A.1 murine-derived macrophages • HepG2
Agent Containment:	Biological Containment Levels: • Mycobacterium tuberculosis: BSL-3 • Other Cell Lines: BSL-3 • Lymphatic: BSL-3 • Respiratory Tissue: BSL-3 • J774A.1 murine-derived macrophages: BSL-2 • HepG2: BSL-2 • H9C2: rat cardiomyoblast: BSL-2 • THP-1: BSL-2
Applicable NIH Guidelines:	• Section III-D-1-b • Section III-D-4-a • Section III-D-4 • Section III-D-2-a • Section III-D-1 • Section III-D-2 • Section III-D

a. **Determination:** Modifications Required
Moved: Melina Kinsey
Second: Judy Hecker

b. **Required modifications:**

1. Tissues, Blood, or Body Fluids - Lymphatic and respiratory tissues – add the specific sources, if possible

2. Primary Cells or Cell lines –
   - Clarify why "Other Cell Lines" is listed as a BSL-3 cell line, and the others are only BSL-2
   - If "Other Cell lines" is BSL-3 why is the storage and usage location in Room 269 (BSL-2)

3. M. bovis BCG, attenuated Mtb strain H37Ra, M. abscessus are mentioned in Recombinant or Synthetic Nucleic Acid Work Description, but the pathogens are not listed in Bacteria, Yeasts, Fungi and Parasites section.

c. **Votes:**

For:	9
Against:	0
Recused:	0
Absent:	1
Abstained:	0

REVIEW OF OTHER AGENDA ITEMS

Melina Kinsey reported the BSL-3 passed the annual re-certification.